Last reviewed · How we verify
montelukast and levocetirizine FDC
montelukast and levocetirizine FDC is a Small molecule drug developed by Hanmi Pharmaceutical Company Limited. It is currently in Phase 1 development.
At a glance
| Generic name | montelukast and levocetirizine FDC |
|---|---|
| Sponsor | Hanmi Pharmaceutical Company Limited |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- PK and Safety Study of HCP1102, HGP0813 and HGP1408 (PHASE1)
- Montelukast and Fexofenadine Versus Montelukast and Levocetrizine Combination in Allergic Rhinitis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- montelukast and levocetirizine FDC CI brief — competitive landscape report
- montelukast and levocetirizine FDC updates RSS · CI watch RSS
- Hanmi Pharmaceutical Company Limited portfolio CI
Frequently asked questions about montelukast and levocetirizine FDC
What is montelukast and levocetirizine FDC?
montelukast and levocetirizine FDC is a Small molecule drug developed by Hanmi Pharmaceutical Company Limited.
Who makes montelukast and levocetirizine FDC?
montelukast and levocetirizine FDC is developed by Hanmi Pharmaceutical Company Limited (see full Hanmi Pharmaceutical Company Limited pipeline at /company/hanmi-pharmaceutical-company-limited).
What development phase is montelukast and levocetirizine FDC in?
montelukast and levocetirizine FDC is in Phase 1.